At the ASCO 2019 annual meeting, Alona Zer discusses the preliminary results from the interim analysis of a phase II study of nivolumab and ipilimumab in previously treated progressive Classic Kaposi Sarcoma (CKS) (NCT03219671).
Questions
1. Could you tell us a little about Classic Kaposi Sarcoma (CKS) and its prognosis? (0:04)
2. What is the rationale for using immune checkpoint inhibitors in patients with CKS? (0:35)
3. What are the limitations of current treatment options for CKS? (1:13)
4. What were the efficacy and safety findings of the phase II study investigating nivolumab and ipilimumab in patients with CKS? (1:50)
5. Which patients are most likely to respond to nivolumab plus ipilimumab? (02:37)
Speaker disclosure: Alona Zer has received a research grant and participated in an advisory board for BMS.
Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.
